PRINCETON, N.J., Nov. 15, 2017 /PRNewswire/ -- Promius Pharma LLC announced today that ZEMBRACE ® SymTouch ® (sumatriptan injection) 3 mg, an acute migraine headache treatment on the market since ...

Dr. Reddy's Laboratories (NYSE: RDY), announced today that the U.S. Food and Drug Administration (FDA) has approved ZEMBRACE™SymTouch™ (sumatriptan succinate) injection, a drug-device combination ...

MUMBAI, Feb 17 (Reuters) - Drug firm Wockhardt Ltd on Tuesday said it will be launching Sumatriptan injections in the U.S. following following final approval from the U.S. Food & Drug Administration.

Tosymra Nasal Spray 10 mg is a Proprietary Acute Migraine Treatment Approved Under the 505(b)2 Pathway Based on Bioequivalence to Imitrex (sumatriptan) Injection 4 mg GlaxoSmithKline Recently Notified ...

Subcutaneous sumatriptan 6 mg is undeniably an excellent treatment of migraine. However, some patients have avoided using 6 mg sumatriptan because of unpleasant or unwanted side effects. To evaluate ...

Strategic Acquisition Helps Build Tonix’s Commercial Capabilities and Infrastructure Ahead of Potential Launch of TNX-102 SL for the Management of Fibromyalgia Acquisition of Zembrace® SymTouch® ...

Chatham-based Tonix Pharmaceuticals Holding Corp. and its wholly owned subsidiary Tonix Medicines Inc. announced June 26 that they entered into an agreement to acquire two fast-acting migraine ...

Strategic Acquisition Helps Build Tonix’s Commercial Capabilities and Infrastructure Ahead of Potential Launch of TNX-102 SL for the Treatment of Fibromyalgia Acute Migraine Products Complement ...

Par Pharmaceutical Companies, Inc. said today it will pay Spectrum Pharmaceuticals, Inc., $20 million for more profits from a collaboration to sell a copycat migraine drug.Par Pharmaceutical Companies ...